Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3037% below fair value
$1.66−0.05 (-2.92%)
Close on Nov 16, 2026Market cap $13.69MP/E –Yield –
Lipocine r&d expenses
Research and development expenses are spending on new products and technology.
Lipocine's R&D Expenses for the twelve months ending Jun 30, 2026 was $10.19M, up 74.0% year over year. For fiscal 2025 it was $8.58M, up 16.8% from the year before. Over ten years it grew -3.8% a year on average. The highest annual figure on record is $15.48M in fiscal 2014.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.58M | +16.8% |
| FY2024 | Dec 31, 2024 | $7.35M | -27.7% |
| FY2023 | Dec 31, 2023 | $10.18M | +18.9% |
| FY2022 | Dec 31, 2022 | $8.56M | +11.6% |
| FY2021 | Dec 31, 2021 | $7.67M | -21.4% |
| FY2020 | Dec 31, 2020 | $9.75M | +30.5% |
| FY2019 | Dec 31, 2019 | $7.47M | +15.5% |
| FY2018 | Dec 31, 2018 | $6.46M | -41.3% |
| FY2017 | Dec 31, 2017 | $11.00M | +36.3% |
| FY2016 | Dec 31, 2016 | $8.08M | -35.8% |
| FY2015 | Dec 31, 2015 | $12.58M | -18.7% |
| FY2014 | Dec 31, 2014 | $15.48M | +202.2% |
| FY2013 | Dec 31, 2013 | $5.12M | +124.6% |
| FY2012 | Dec 31, 2012 | $2.28M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.04M | -4.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.76M | +160.4% |
| Q4 FY2025 | Dec 31, 2025 | $2.68M | +149.6% |
| Q3 FY2025 | Sep 30, 2025 | $2.71M | +70.8% |
| Q2 FY2025 | Jun 30, 2025 | $2.14M | +14.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.06M | -62.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.07M | -35.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.59M | -44.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.87M | -25.5% |
| Q1 FY2024 | Mar 31, 2024 | $2.82M | -9.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.67M | +0.3% |
| Q3 FY2023 | Sep 30, 2023 | $2.88M | +37.1% |
| Q2 FY2023 | Jun 30, 2023 | $2.52M | -13.2% |
| Q1 FY2023 | Mar 31, 2023 | $3.11M | +64.5% |
| Q4 FY2022 | Dec 31, 2022 | $1.67M | -25.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.10M | -11.2% |
| Q2 FY2022 | Jun 30, 2022 | $2.90M | +97.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.89M | +19.4% |
| Q4 FY2021 | Dec 31, 2021 | $2.25M | -9.1% |
| Q3 FY2021 | Sep 30, 2021 | $2.37M | -4.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.46M | -35.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.58M | -37.1% |
| Q4 FY2020 | Dec 31, 2020 | $2.48M | +34.7% |
| Q3 FY2020 | Sep 30, 2020 | $2.49M | +45.2% |
| Q2 FY2020 | Jun 30, 2020 | $2.27M | +15.5% |
| Q1 FY2020 | Mar 31, 2020 | $2.51M | +28.8% |
| Q4 FY2019 | Dec 31, 2019 | $1.84M | -15.6% |
| Q3 FY2019 | Sep 30, 2019 | $1.71M | +20.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.96M | +32.5% |
| Q1 FY2019 | Mar 31, 2019 | $1.95M | +41.5% |
| Q4 FY2018 | Dec 31, 2018 | $2.18M | +23.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.42M | -30.5% |
| Q2 FY2018 | Jun 30, 2018 | $1.48M | -63.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.38M | -55.3% |
| Q4 FY2017 | Dec 31, 2017 | $1.77M | +33.0% |
| Q3 FY2017 | Sep 30, 2017 | $2.05M | +35.8% |
| Q2 FY2017 | Jun 30, 2017 | $4.11M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.08M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.33M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.51M | – |
See a number that looks wrong?